(Q45961748)

18 December 2017

title

A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia. (English)

1 reference

18 December 2017

1 reference

1 reference

1 reference

placebo-controlled trial

1 reference

based on heuristic

inferred from title

author

Jean-Christophe Corvol

6

1 reference

18 December 2017

Claudia Trenkwalder

1

Claudia Trenkwalder

1 reference

PubMed ID

26990766

18 December 2017

Andres Ceballos-Baumann

5

Andres Ceballos-Baumann

1 reference

18 December 2017

Christine Tranchant

Christine Tranchant

15

0 references

Fabrizio Stocchi

Fabrizio Stocchi

14

0 references

Daniela Berg

2

Daniela Berg

2 references

ORCID Public Data File 2021

18 December 2017

Jean-Philippe Azulay

9

Jean-Philippe Azulay

1 reference

18 December 2017

3

Olivier Rascol

1 reference

18 December 2017

20

Jean-Luc Houeto

1 reference

18 December 2017

22

Thérèse Di Paolo

1 reference

18 December 2017

11

Luc Defebvre

1 reference

18 December 2017

16

Pascal Derkinderen

1 reference

18 December 2017

Annamária Jakab

26

Annamaria Jakab

1 reference

18 December 2017

Karla M. Eggert

4

Karla Eggert

1 reference

18 December 2017

Hans-Ulrich P Hockey

24

Hans-Ulrich Hockey

1 reference

18 December 2017

author name string

Alexander Storch

7

1 reference

18 December 2017

Lin Zhang

8

1 reference

18 December 2017

Emmanuel Broussolle

10

1 reference

18 December 2017

Christian Geny

12

1 reference

18 December 2017

Michal Gostkowski

13

1 reference

18 December 2017

Franck Durif

17

1 reference

18 December 2017

Alberto J Espay

18

1 reference

18 December 2017

Andrew Feigin

19

1 reference

18 December 2017

Johannes Schwarz

21

1 reference

18 December 2017

Dominik Feuerbach

23

1 reference

18 December 2017

Judith Jaeger

25

1 reference

18 December 2017

Donald Johns

27

1 reference

18 December 2017

Gurutz Linazasoro

28

1 reference

18 December 2017

Paul Maruff

29

1 reference

18 December 2017

Izabela Rozenberg

30

1 reference

18 December 2017

Judit Sovago

31

1 reference

18 December 2017

Markus Weiss

32

1 reference

18 December 2017

Baltazar Gomez-Mancilla

33

1 reference

18 December 2017

language of work or name

English

0 references

publication date

15 March 2016

1 reference

18 December 2017

published in

Movement Disorders

1 reference

18 December 2017

Levodopa-induced dyskinesias

cites work

1 reference

Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature

21 January 2018

1 reference

Impact of the motor complications of Parkinson's disease on the quality of life

21 January 2018

1 reference

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease

21 January 2018

1 reference

Nicotine is neuroprotective when administered before but not after nigrostriatal damage in rats and monkeys

21 January 2018

1 reference

Nicotine, but not cotinine, partially protects dopaminergic neurons against MPTP-induced degeneration in mice

21 January 2018

1 reference

Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.

21 January 2018

1 reference

Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates.

21 January 2018

1 reference

21 January 2018

1 reference

Nicotine, but neither the alpha4beta2 ligand RJR2403 nor an alpha7 nAChR subtype selective agonist, protects against a partial 6-hydroxydopamine lesion of the rat median forebrain bundle.

21 January 2018

1 reference

Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease

21 January 2018

1 reference

Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats

21 January 2018

1 reference

Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys

21 January 2018

1 reference

3-[(2,4-Dimethoxy)benzylidene]-anabaseine dihydrochloride protects against 6-hydroxydopamine-induced parkinsonian neurodegeneration through α7 nicotinic acetylcholine receptor stimulation in rats

21 January 2018

1 reference

Nicotinic receptor agonists reduce L-DOPA-induced dyskinesias in a monkey model of Parkinson's disease

21 January 2018

1 reference

AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation

21 January 2018

1 reference

JN403, in vitro characterization of a novel nicotinic acetylcholine receptor alpha7 selective agonist.

21 January 2018

1 reference

The selective nicotinic acetylcholine receptor alpha7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain

21 January 2018

1 reference

The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetize

21 January 2018

1 reference

TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia

21 January 2018

1 reference

Discovery of (2S,3R)-N-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]benzo[b]furan-2-carboxamide (TC-5619), a selective α7 nicotinic acetylcholine receptor agonist, for the treatment of cognitive disorders

21 January 2018

1 reference

EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors

21 January 2018

1 reference

Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers

21 January 2018

1 reference

Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia

21 January 2018

1 reference

A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia

21 January 2018

1 reference

Normalizing effects of EVP-6124, an α-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia

21 January 2018

1 reference

Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology

21 January 2018

1 reference

Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson disease.

21 January 2018

1 reference

Practice effects associated with the repeated assessment of cognitive function using the CogState battery at 10-minute, one week and one month test-retest intervals.

21 January 2018

1 reference

Which dyskinesia scale best detects treatment response?

21 January 2018

1 reference

Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/MDS.26569

1 reference

18 December 2017

PubMed ID

26990766

1 reference

18 December 2017